Mesa Laboratories, Inc. to Issue Quarterly Dividend of $0.16 (NASDAQ:MLAB)

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend on Monday, July 6th. Shareholders of record on Monday, August 31st will be given a dividend of 0.16 per share by the medical instruments supplier on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 31st.

Mesa Laboratories has a dividend payout ratio of 5.2% meaning its dividend is sufficiently covered by earnings.

Mesa Laboratories Stock Performance

Shares of MLAB traded down $2.98 during midday trading on Monday, hitting $102.56. 156,671 shares of the stock traded hands, compared to its average volume of 218,561. Mesa Laboratories has a 1-year low of $55.45 and a 1-year high of $113.99. The firm has a market capitalization of $566.13 million, a PE ratio of 15.45 and a beta of 0.93. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72. The business’s 50 day moving average price is $102.05 and its two-hundred day moving average price is $92.56.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same period last year, the business earned ($1.31) EPS.

Insider Activity

In related news, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the sale, the senior vice president directly owned 6,377 shares in the company, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John Sakys sold 2,827 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This represents a 12.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 8,277 shares of company stock valued at $770,122. Company insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Mesa Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesa Laboratories during the fourth quarter valued at $27,000. Kestra Advisory Services LLC acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at $55,000. BNP Paribas Financial Markets boosted its position in shares of Mesa Laboratories by 115.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 421 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Mesa Laboratories by 432.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 684 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.